Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 19, 2026, 10:15 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 167 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: amantadine Clear all
Completed Not applicable Interventional Accepts healthy volunteers Results available

Treatment With Namenda in Women at Risk for Cognitive Decline

NCT00242632
View directory record Official record
Conditions
Dementia
Interventions
Namenda
Drug
Lead sponsor
Stanford University
Other
Eligibility
50 Years to 65 Years · Female only
Enrollment
22 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2004 – 2009
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated Jun 14, 2017 · Synced Oct 19, 2026, 10:15 AM EDT
Completed Not applicable Interventional Results available

Memantine for Neuroprotection and Cognitive Enhancement Following Traumatic Brain Injury

NCT02240589
View directory record Official record
Conditions
Traumatic Brain Injury
Interventions
Memantine, Placebo
Drug
Lead sponsor
Indiana University
Other
Eligibility
18 Years to 65 Years
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
1
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Aug 30, 2017 · Synced Oct 19, 2026, 10:15 AM EDT
Not yet recruiting Phase 1 Interventional

Escalating Doses of Memantine in Down Syndrome (MEDS-123)

NCT07531940
View directory record Official record
Conditions
Down Syndrome, Intellectual Disability, Alzheimer Dementia (AD)
Interventions
Memantine
Drug
Lead sponsor
University Hospitals Cleveland Medical Center
Other
Eligibility
18 Years to 32 Years
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Oct 5, 2026 · Synced Oct 19, 2026, 10:15 AM EDT
Completed Phase 3 Interventional

Safinamide in Idiopathic Parkinson's Disease (IPD) With Motor Fluctuations, as add-on to Levodopa

NCT00627640
View directory record Official record
Conditions
Idiopathic Parkinson's Disease
Interventions
Safinimide 50-100 mg/day, Matching Placebo
Drug
Lead sponsor
Newron Pharmaceuticals SPA
Industry
Eligibility
30 Years to 80 Years
Enrollment
549 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2012
U.S. locations
28
States / cities
Birmingham, Alabama • Phoenix, Arizona • Scottsdale, Arizona + 24 more
Source: ClinicalTrials.gov public record
Updated Mar 29, 2013 · Synced Oct 19, 2026, 10:15 AM EDT
Completed Phase 1 Interventional

Prepulse Inhibition of Startle in Cocaine Dependence - 7

NCT00015249
View directory record Official record
Conditions
Cocaine-Related Disorders, Substance-Related Disorders
Interventions
Amantadine
Drug
Lead sponsor
National Institute on Drug Abuse (NIDA)
NIH
Eligibility
18 Years to 60 Years · Male only
Healthy volunteers
Healthy volunteers not accepted
Timeline
1997 – 1998
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jan 12, 2017 · Synced Oct 19, 2026, 10:15 AM EDT
Terminated Phase 4 Interventional

Memantine or Riluzole Prophylaxis for Corticosteroid-induced Mood and Declarative Memory Changes

NCT00283309
View directory record Official record
Conditions
Mood, Memory Deficit
Interventions
Memantine, Riluzole
Drug
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
18 Years to 70 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2007
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Apr 23, 2013 · Synced Oct 19, 2026, 10:15 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers

A Pilot Clinical Trial Of Memantine for Essential Tremor

NCT00439699
View directory record Official record
Conditions
Essential Tremor
Interventions
Memantine
Drug
Lead sponsor
VA Greater Los Angeles Healthcare System
Federal
Eligibility
18 Years and older
Enrollment
16 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2009
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Jun 22, 2012 · Synced Oct 19, 2026, 10:15 AM EDT
Terminated Phase 3 Interventional Results available

Efficacy and Safety of Amantadine Hydrogen Chloride (HCl) ER Tablets in Parkinson's Disease Subjects With LID

NCT02153632
View directory record Official record
Conditions
Parkinson's Disease, Levodopa Induced Dyskinesia (LID)
Interventions
amantadine HCl ER, Placebo
Drug
Lead sponsor
Adamas Pharmaceuticals, Inc.
Industry
Eligibility
30 Years to 85 Years
Enrollment
135 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
24
States / cities
Tucson, Arizona • Fountain Valley, California • Irvine, California + 21 more
Source: ClinicalTrials.gov public record
Updated Feb 16, 2022 · Synced Oct 19, 2026, 10:15 AM EDT
Completed Phase 2 Interventional

Memantine for the Treatment of Cognitive Impairment in Systemic Lupus Erythematosus

NCT03527472
View directory record Official record
Conditions
Lupus Erythematosus, Systemic
Interventions
Memantine, Placebo
Drug
Lead sponsor
Vanderbilt University Medical Center
Other
Eligibility
18 Years to 70 Years
Enrollment
111 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2026
U.S. locations
3
States / cities
Cleveland, Ohio • Nashville, Tennessee • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Apr 22, 2026 · Synced Oct 19, 2026, 10:15 AM EDT
Terminated Phase 1 Interventional

Temozolomide, Memantine Hydrochloride, Mefloquine, and Metformin Hydrochloride in Treating Patients With Glioblastoma Multiforme After Radiation Therapy

NCT01430351
View directory record Official record
Conditions
Glioblastoma, Gliosarcoma, Supratentorial Glioblastoma
Interventions
Mefloquine, Memantine Hydrochloride, Metformin Hydrochloride, Temozolomide
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
144 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2025
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated May 7, 2025 · Synced Oct 19, 2026, 10:15 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Memantine Effects on Sensorimotor Gating and Neurocognition in Schizophrenia

NCT03860597
View directory record Official record
Conditions
Schizophrenia, Schizo Affective Disorder, Schizoaffective Disorder, Healthy
Interventions
Memantine, Placebos
Drug
Lead sponsor
University of California, San Diego
Other
Eligibility
18 Years to 50 Years
Enrollment
42 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2021
U.S. locations
1
States / cities
San Diego, California
Source: ClinicalTrials.gov public record
Updated Dec 21, 2022 · Synced Oct 19, 2026, 10:15 AM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

A 10 Week Open-Label Pilot Study to Evaluate the Effectiveness and Safety of Memantine(Namenda) as Augmentation Therapy in Patients With Generalized Anxiety Disorder

NCT00411398
View directory record Official record
Conditions
General Anxiety Disorder, Social Anxiety Disorder
Interventions
Namenda/Memantine
Drug
Lead sponsor
State University of New York - Upstate Medical University
Other
Eligibility
18 Years to 64 Years
Enrollment
15 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2010
U.S. locations
1
States / cities
Syracuse, New York
Source: ClinicalTrials.gov public record
Updated Dec 10, 2014 · Synced Oct 19, 2026, 10:15 AM EDT
Recruiting Phase 2 Interventional

Memantine +/- Raloxifene for Cognitive Preservation After Radiation Therapy to the Brain

NCT07470606
View directory record Official record
Conditions
Brain Tumor
Interventions
Memantine, Raloxifene
Drug
Lead sponsor
The University of Texas Health Science Center at San Antonio
Other
Eligibility
18 Years and older
Enrollment
108 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2031
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Sep 22, 2026 · Synced Oct 19, 2026, 10:15 AM EDT
Completed Phase 2 Interventional

Amantadine Therapy for Cognitive Impairment in Long COVID

NCT06055244
View directory record Official record
Conditions
Long COVID, Post-COVID19 Condition, Post-Acute COVID19 Syndrome
Interventions
Amantadine
Drug
Lead sponsor
Ohio State University
Other
Eligibility
18 Years and older
Enrollment
64 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Jan 27, 2026 · Synced Oct 19, 2026, 10:15 AM EDT
Completed Phase 4 Interventional

Study of Memantine in Assessment of Selected Measures of Volumetric Magnetic Resonance Imaging (MRI) and Cognition in Moderate AD (Alzheimer's Disease)

NCT00334906
View directory record Official record
Conditions
Alzheimer's Disease
Interventions
memantine HCl
Drug
Lead sponsor
Forest Laboratories
Industry
Eligibility
50 Years and older
Enrollment
75 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2005
U.S. locations
1
States / cities
Jersey City, New Jersey
Source: ClinicalTrials.gov public record
Updated Jan 7, 2008 · Synced Oct 19, 2026, 10:15 AM EDT
Active, not recruiting Phase 2 Interventional

Evaluating the Neurophysiologic and Clinical Effects of Single Dose Drug Challenge

NCT05418049
View directory record Official record
Conditions
Fragile X Syndrome
Interventions
Baclofen, Memantine, Roflumilast, Placebo
Drug
Lead sponsor
Children's Hospital Medical Center, Cincinnati
Other
Eligibility
18 Years to 45 Years
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Dec 23, 2025 · Synced Oct 19, 2026, 10:15 AM EDT
Completed Phase 4 Interventional

Memantine for Corticosteroid-Induced Mood and Declarative Memory Changes

NCT00280774
View directory record Official record
Conditions
Physiological Effects of Drugs
Interventions
Memantine
Drug
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
18 Years to 70 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Jan 25, 2008 · Synced Oct 19, 2026, 10:15 AM EDT
Completed Not applicable Interventional Results available

An Open Label Trial of Memantine in the Treatment of Bulimia Nervosa and Body Dysmorphic Disorder

NCT01038128
View directory record Official record
Conditions
Bulimia Nervosa, Body Dysmorphic Disorder
Interventions
Memantine
Drug
Lead sponsor
Mclean Hospital
Other
Eligibility
18 Years to 65 Years
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
1
States / cities
Belmont, Massachusetts
Source: ClinicalTrials.gov public record
Updated May 4, 2015 · Synced Oct 19, 2026, 10:15 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Effects of Memantine on Magnetic Resonance (MR) Spectroscopy in Subjects at Risk for Alzheimer's Disease

NCT00933608
View directory record Official record
Conditions
Alzheimer's Disease
Interventions
memantine, Placebo
Drug
Lead sponsor
NYU Langone Health
Other
Eligibility
55 Years to 90 Years
Enrollment
17 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2011
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Oct 21, 2014 · Synced Oct 19, 2026, 10:15 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Biomarker Strategies for Medication-Enhanced Cognitive Training in Schizophrenia

NCT01555697
View directory record Official record
Conditions
Schizophrenia
Interventions
Memantine, Placebo
Drug
Lead sponsor
University of California, San Diego
Other
Eligibility
18 Years to 55 Years
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2019
U.S. locations
1
States / cities
San Diego, California
Source: ClinicalTrials.gov public record
Updated Oct 4, 2022 · Synced Oct 19, 2026, 10:15 AM EDT
Completed Phase 4 Interventional Results available

Memantine (10mg BID) for the Frontal and Temporal Subtypes of Frontotemporal Dementia

NCT00545974
View directory record Official record
Conditions
Frontal Lobe Dementia, Frontotemporal Lobe Dementia, Semantic Dementia
Interventions
memantine, Placebo pill
Drug
Lead sponsor
University of California, San Francisco
Other
Eligibility
40 Years to 80 Years
Enrollment
81 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2012
U.S. locations
9
States / cities
Los Angeles, California • San Francisco, California • Jacksonville, Florida + 6 more
Source: ClinicalTrials.gov public record
Updated Nov 17, 2020 · Synced Oct 19, 2026, 10:15 AM EDT
Terminated Phase 4 Interventional

Namenda to Prevent Post-Operative Delirium

NCT00303433
View directory record Official record
Conditions
Delirium, Post-Operative States
Interventions
Namenda
Drug
Lead sponsor
University of Rochester
Other
Eligibility
50 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006
U.S. locations
1
States / cities
Rochester, New York
Source: ClinicalTrials.gov public record
Updated Jun 3, 2015 · Synced Oct 19, 2026, 10:15 AM EDT
Terminated Phase 3 Interventional Results available

Efficacy Study of Amantadine to Treat Gait Dysfunction and Freezing in Parkinson's Disease

NCT01652534
View directory record Official record
Conditions
Parkinson's Disease
Interventions
Amantadine, Placebo
Drug
Lead sponsor
Northwestern University
Other
Eligibility
18 Years to 85 Years
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2015
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Nov 13, 2019 · Synced Oct 19, 2026, 10:15 AM EDT
Completed Phase 4 Interventional

An Open-Label Trial of Memantine in the Treatment of Binge Eating Disorder

NCT00330655
View directory record Official record
Conditions
Binge Eating Disorder
Interventions
memantine
Drug
Lead sponsor
Mclean Hospital
Other
Eligibility
16 Years to 65 Years
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
1
States / cities
Belmont, Massachusetts
Source: ClinicalTrials.gov public record
Updated Aug 14, 2007 · Synced Oct 19, 2026, 10:15 AM EDT